AR-C118901

AR-C118901 is a synthetic small molecule identified as an inhibitor of inducible Nitric Oxide Synthase (iNOS). Its mechanism of action involves binding to the oxygenase domain of iNOS, as evidenced by structural studies (PDB entry 3E6T). By inhibiting iNOS, AR-C118901 aims to reduce the production of nitric oxide, which plays a role in various pathological conditions. Preclinical research suggests its potential therapeutic applications in inflammatory conditions, arthritis, stroke, septic shock, and cancer. While the 'AR-C' prefix typically indicates development by AstraZeneca, this specific compound's development status as a therapeutic agent is primarily in the preclinical research phase, with a related compound, [18F]FBAT, being explored as a PET imaging tracer for iNOS.

Other names

5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE5-(4'-amino-1'-ethyl-5',8'-difluorospiro[piperidine-4,2'-quinazoline]-1-carbonyl)-3,4-dihydropyridine-2-carbonitrile